NascaCell Technologies AG
Archemix and NascaCell expand strategic alliance for aptamer-based drug discovery
NascaCell Technologies AG / Alliance Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- CAMBRIDGE, MA and MUNICH, GERMANY – February 12, 2008 – Archemix Corp. and NascaCell Technologies AG announced today an expansion of their strategic alliance focused on the use and development of aptamers for drug discovery applications. Under the terms of the new agreement, NascaCell receives non-exclusive rights to uses of aptamers for target validation, mode of action studies, drug discovery, and aptamer structure-based drug design. Future aptamer technology improvements will be cross-licensed between the companies and Archemix will have the option of contracting NascaCell to generate aptamers for its own applications. Specific financial terms were not disclosed. About Aptamers Aptamers are synthetically-derived oligonucleotides, or short nucleic acid sequences, that bind to protein targets with high affinity and specificity and can be designed to have a specified duration of action. Aptamers represent an emerging class of potential therapeutic agents that Archemix believes may have broad application to treat a variety of human diseases. About Archemix Archemix is a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics. Using Archemix's proprietary processes for discovering aptamers, which are protected by its patent portfolio, Archemix is developing aptamer product candidates for cardiovascular and hematological diseases and cancer. In addition, Archemix has licensed its intellectual property to third parties to develop their own aptamer product candidates. To date, Archemix has licensed its intellectual property to discover and develop aptamer product candidates to nine biotechnology and pharmaceutical companies, including Pfizer, Merck Serono, Takeda Pharmaceuticals and Elan Pharma. About NascaCell NascaCell Technologies AG, located in Munich, Germany, is a worldwide leading provider of custom aptamers for target validation and drug discovery. The company has a strong patent position in the field with access to over 380 patents and patent applications. NascaCell's automated in vitro selection platform allows the rapid generation of aptamers for almost any target of choice (e.g., kinases, proteases, and growth factors). In addition, NascaCell develops a line of products and drug development candidates based on the MicrobodyTM technology. This press release includes forward-looking statements regarding Archemix’s intellectual property estate and proprietary technologies for discovery and development of aptamer drugs. Any statement describing Archemix’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Archemix goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Archemix’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Archemix’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Archemix. As a result, you are cautioned not to rely on these forward-looking statements. Archemix Contact: NascaCell Contact: Adriana Jenkins InvestorPress GmbH Archemix Corp. Georg Breu +1-617-744-1713 Tel.: +49 (0)89 55 96 98 75 info@investorpress.de 12.02.2008 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found